Connect with us


Manus closes £1.2m funding round to support neuromotor pen launch

Avatar photo



Manus is rolling out its NeuroMotor Pen later this year

Edinburgh-based MedTech company Manus Neurodynamica has closed a £1.2m funding round to support the launch of its digital pen which provides an early warning of Parkinson’s disease and other neurological conditions.

Manus is rolling out its NeuroMotor Pen later this year, initially focusing on the UK and Benelux markets, while also progressing work to secure regulatory approval to start selling in the US.

Investors in the funding round included the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures, profit with purpose investor SIS Ventures and Old College Capital, the University of Edinburgh’s venture fund.

The NeuroMotor Pen employs sensors linked with analytical software which analyses the slightest limb and hand movements to help doctors assess whether a patient has early signs of Parkinson’s or other neurological conditions.

Manus CEO Dr Rutger Zietsma said: “Having spent more than 10 years developing, trialling and refining our first product, we can finally look forward to seeing our NeuroMotor Pens implemented more broadly and making a real difference to the lives of people living with Parkinson’s and other neurological conditions.

“Through faster and simpler diagnoses and objective patient monitoring with digital record keeping, we can help streamline the pathway and deliver more successful treatment outcomes for the fastest growing neurological condition in the world.”

Rob Halliday, fund manager at SIS Ventures added: “Manus is one of Scotland’s most promising early stage MedTech companies, with the potential to make a huge impact.

“With its disruptive technology, mission-led approach, and ambitious management team, Manus is exactly the kind of business we look to invest in at SIS Ventures. Working along with the other investors, we are very pleased to support Rutger and his team through their next phase of growth and impact creation. “

The company is currently in advanced talks to supply the pens to a UK-based primary care group, following a development contract with NHS England to develop a version that can be used in GP surgeries. The pen has passed clinical trials with the NHS in the North East of England and Scotland and is currently being used by Northumbria NHS Foundation Trust.

Funding rounds, totalling £5m to date, including a £750,000 financing round, closed in May last year, have been led by health tech investors Par Equity with support from the Scottish Investment Bank, the investment arm of Scottish Enterprise, and Old College Capital.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories